5th DVFA Life Science Conference

5th DVFA Life Science Conference
Healthcare Services & Healthcare Suppliers
- Essentials for affordable Healthcare -
5th DVFA Symposium Life Science followed by a Get Together
8 May 2012, from 9 a.m.
DVFA Center, Frankfurt/Main
Supported by
Media Partner
Society of Investment Professionals in Germany
Life Science Conference
Dear attendee,
DVFA Committee Life Science is proud to present the 5th DVFA Life Science Conference in
Frankfurt/Main.
The Life Science Symposium focuses on the issue of how to fund the growing demand for
healthcare services and products in the wake of aging populations and the sovereign debt
crisis. The growing funding shortfall is acting as a catalyst for necessary structural changes in
healthcare and for Healthcare Services Providers & Suppliers. Innovative strategies and
affordable products are needed in all areas of healthcare in order to increase efficiency,
effectiveness and quality. The care of chronically sick and multimorbid patients represents a
formidable challenge to the present system.
I am very pleased to welcome you in Frankfurt and wish you an interesting and informative
conference. If there is anything DVFA can do to make you feel more comfortable, or if you have
questions, please do not hesitate to contact myself or my team any time.
Kind regards,
Ralf Frank MBA
Managing Director
DVFA GmbH
3
Life Science Conference
DISCLAIMER
This brochure contains information from sources believed to be reliable but has not been verified or
testified. The corporate data provided has been transmitted and converted electronically. Therefore, the
information cannot be guaranteed to be secure or error-free as the transmitted and converted
information could be intercepted, corrupted, lost or incomplete.
Thus, DVFA does not accept liability for any errors or omissions regarding the contents of this
information. The conference brochure is provided for information purposes and should not be construed
as a solicitation or offer to buy or sell any securities or related financial instruments.
Any copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and
may be unlawful.
Please note that the data given in this brochure may be rounded. Deviations may thus occur, e.g.
regarding percentage figures.
 2012 DVFA GmbH
ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or
transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise,
without the prior written permission of the publisher and the copyright holder.
Editorial Close: 03 May 2012
4
Life Science Conference
Society of Investment Professionals in Germany
Table of Contents
Page
Programme Symposium ............................................................................................................. Speakers and Moderators .......................................................................................................... 8
Sponsors .................................................................................................................................... 17
Organizational Notes ................................................................................................................ 5
Life Science Conference
Programme Symposium
Tuesday, 8 May 2012
08:45  Check-in
09:00  Welcome
Ralf Frank, Managing Director, DVFA
Dr. Markus Manns, Union Investment Privatfonds and Chairman
DVFA Commission Life Science
09:10  Healthcare Services - Essentials for affordable Healthcare An Introduction
Michael Burkhart, Partner, PricewaterhouseCoopers
09:45  Redefining German Health Care - Moving to Value-Based System
Dr. Clemens Guth, Managing Director, Artemed Kliniken
10:20  Company Presentation I: Rhön-Klinikum
Dr. Erik Hamann, CFO
10:50  Coffee Break
11:10  Company Presentation II: Asklepios Kliniken
Stephan Leonhard, CFO
11:45  Panel I: Healthcare Services - Successful Strategies from a Capital Market Perspective
Sebastien Buch, Union Investment Privatfonds
Michael Burkhart, Partner, PricewaterhouseCoopers
Stefan Höfer, Deutsche Börse
Dr. Volker Wendel, CFO, AMEOS Gruppe
Moderation: Dr. Christa Bähr, DZ BANK and Chairwoman
DVFA Commission Life Science
12:45  Lunch
13:30  Healthcare Suppliers - Essentials for affordable Healthcare Manuela Müller-Gerndt, Healthcare Leader IBM
14:05  Company Presentation III: NEXUS AG
Dr. Ingo Behrendt, CEO
14:40  Company Presentation IV: CompuGroup Medical AG
Christian B. Teig, CFO
15:10  Coffee Break
15:30  Company Presentation V: QIAGEN
Dr. Stephen Little, VP Global Personalized Healthcare
16:05 
Panel II: Healthcare Suppliers - Increase in Quality & Efficiency?
Kai Brüning, ApoAsset Management
Dr. Stephen Little, VP Global Personalized Healthcare
Manuela Müller-Gerndt, Healthcare Leader, IBM
Prof. Dr. Jörg Vienken, VP BioSciences, Fresenius Medical Care Deutschland
Moderation: Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP Rechtsanwälte
17:00  Get Together
Subject to modifications!
7
Life Science Conference
Speakers & Moderators
Dr. Christa Bähr, CEFA, CFA, DZ BANK AG and Chairwoman DVFA Commission Life Science
Dr. Ingo Behrendt, CEO, NEXUS AG
Kai Brüning, CEFA, Senior Portfolio Manager, ApoAsset Management
Sebastién Buch, CFA, Portfoliomanager, Union Investment Privatfonds
Michael Burkhart, Partner und Leiter Bereich Gesundheitswesen und Pharma,
PricewaterhouseCoopers
Dr. Clemens Guth, Managing Director, Artemed Kliniken
Dr. Erik Hamann, CFO, Rhön-Klinikum
Stefan Höfer, Vice President Issuer & Investor Markets, Deutsche Börse AG
Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP Rechtsanwälte
Stephan Leonhard, CFO, Asklepios Kliniken
Dr. Stephen Little, VP Global Personalized Healthcare, QIAGEN
Dr. Markus Manns, Union Investment Privatfonds and Chairman DVFA Commission Life
Science
Manuela Müller-Gerndt, Healthcare Leader, IBM
Christian B. Teig, CFO, CompuGroup Medical AG
Prof. Dr. Jörg Vienken, VP BioSciences, Fresenius Medical Care Deutschland
Dr. Volker Wendel, CFO, AMEOS Gruppe
The following information is provided by the respective speakers and moderators. DVFA cannot assume any
responsibility for the correctness and completeness of this information.
8
Life Science Conference
Dr. Christa Bähr, CEFA, CFA, DZ BANK AG & Chairwoman DVFA Committee Life Science
Christa Bähr joined DZ BANK Equity Research in January 2000 to build up
the Life Science Team. In July 2003 she became group leader of the newly
founded group which includes Life Science, Chemicals, Telecoms, Real
Estate and Financials. Besides she is in her position as lead analyst
healthcare responsible for the fundamental analysis of healthcare stocks.
She is CEFA Investment Analyst/DVFA und Chartered Financial Analyst
(CFA) and chairwoman of the DVFA Commission Life Science.
Following an apprenticeship as bank clerk at Commerzbank AG, she studied
business administration and economics at the University of Cologne. After that she worked as
an assistant at the Seminar for Public Finance at the University of Cologne and obtained her
doctorate in economics (Dr. rer. pol.) in 1994. Before and during her studies, she worked for
Commerzbank AG in Bonn, Cologne and London. From 1994 to 1998, she worked for
Bankgesellschaft Berlin AG in Berlin, and from 1998 to 1999 for BHF-BANK AG/ING Group in
Frankfurt as investment analyst for pharmaceutical, healthcare, biotechnology and chemical
stocks.
Dr. Ingo Behrendt, NEXUS AG
Born 1965 in Hamburg, lives in Konstanz, 2 children
Dr. Ingo Behrendt is a member of the board of NEXUS AG since 2000, and
is in the position of CEO since 2002.
NEXUS has been growing to one of the leading Healthcare IT companies in
the last 10 years. NEXUS AG is listed at Frankfurt Stock exchange.
Mr. Behrendt is trained as a banker, studied business administration at
the University of Applied Sciences Worms (Master of Business Administration) and computer
science at the University of Konstanz (Diploma in Information Science). In addition, Dr.
Behrendt graduated (with a Fulbright scholarship) at Clark University, Massachusetts (USA)
from an MBA degree program. At the Technical University of Berlin, Dr. Behrendt gained a
Ph.D. in the field of software architecture.
Dr. Behrendt has extensive international experience in the IT business, which he has acquired
in various commercial and technical functions in the time of 1992-2000 at Siemens AG. In
particular, responsibility for major software development projects and international customer
projects were the focus of activities at Siemens AG. As the author of several books and a
member of the supervisory board of a nursing home chain, Dr. Behrendt uses his experience
also outside of NEXUS AG.
9
Life Science Conference
Sébastien Buch, CFA, Union Investment Privatfonds
Sébastien Buch joined the equity portfolio management of Union
Investment in January 2005. He is responsible for two equity funds and
covers the international health care sector.
From March 2002 to December 2004 Sébastien worked as a senior
portfolio manager at DWS Investment in Frankfurt, where he managed
three international health care funds. He started his career as a junior
portfolio manager in September 2000 at Zurich Investmentgesellschaft
mbH in Frankfurt.
Following a vocational training programme at Deutsche Bank in Lörrach, Sébastien studied
business administration and economics at the University of Applied Sciences in Aachen and at
the Universities of Alicante (Spain) and Lille (France). In the year 2000 he graduated with a
degree in business administration and the “maitrise en sciences économiques mention
économie internationale”.
Kai Brüning, CEFA, apo Asset Management GmbH
Kai Brüning is a Senior Portfolio Manager at apo Asset Management,
which is a majority owned subsidiary of Deutsche Apotheker & Ärztebank.
He manages global healthcare funds for institutional and private clients.
Mr. Brüning works in the healthcare investment area for over a decade.
Before joining apo Asset he worked with ADIG/ Cominvest and Deka
Investment.
Mr. Brüning holds a Diplom-Kaufmann degree from the University of
Cologne and is a DVFA/CEFA degree holder. He was awarded by Thomson
Extel surveys in the past and is a board member of the DVFA Life Science
Commission.
10
Life Science Conference
Michael Burkhart, PricewaterhouseCoopers
Michael Burkhart ist Partner im Kompetenz-Zentrum Healthcare im
Bereich Wirtschaftsprüfung und prüfungsnahe Beratung und Leiter des
Bereichs Gesundheitswesen und Pharma bei PricewaterhouseCoopers.
Herr Burkhart verfügt über 14 Jahre Berufserfahrung im
Gesundheitswesen, davon insbesondere im Bereich:
 Jahresabschlussprüfung von Universitätsklinika
- Prüfungsleitung bei Universitätsklinika (Universitätsklinikum
Heidelberg, Universitätsklinikum Marburg, Universitätsklinikum
Gießen, Universitätsklinikum Aachen)
- Unterstützung der DFG in Bezug auf die Erstellung von Kriterien zur
Transparenzrechnung/Trennungsrechnung
 Jahresabschlussprüfung (Einzel- und Konzernabschluss) von Krankenhäusern, Alten- und
Pflegeheimen und Reha-Einrichtungen verschiedener Rechtsformen und Größen (inkl.
psychiatrischer und neurologischer Einrichtungen), inklusive einer im Prime Segment
gelisteten Klinikkette
 Prüfung von Businessplänen und Due Diligence bei Alten- und Pflegeheimen und
Krankenhäusern
 Erstellung von Bilanzierungsrichtlinien für psychiatrische Einrichtungen
 Verantwortlicher Partner für Benchmarking Healthcare und psychiatrische Einrichtungen
 Mitglied im europäischen EMEA Healthcare Leadership Team
Herr Michael Burkhart absolvierte das Studium der Betriebswirtschaftslehre an der Universität
Passau. Er spricht fließend Englisch.
Michael Burkhart ist Wirtschaftsprüfer und Steuerberater. Er gehört PricewaterhouseCoopers
seit 1994 an.
Dr. Clemens Guth, Artemed Kliniken
Clemens Guth is the chief executive of three German hospitals and a
member of the executive board at Artemed Kliniken, a German national
hospital provider. Earning his M.D. at Imperial College London, Dr. Guth
began his career as a Junior Doctor at the Chelsea & Westminster
Hospital in London. Subsequently, he became a health care consultant for
McKinsey & Company. After earning his M.B.A. at Harvard Business
School with honors, he returned to hospitals but as a manager. Dr. Guth
collaborates with Prof. Michael E. Porter on health systems research since
2006 and is a Senior Institute Associate at the Institute for Strategy and Competitiveness at
Harvard Business School. He is a scholarship winner of the German National Academic
Foundation and the German Academic Exchange Service program.
11
Life Science Conference
Dr. Erik Hamann, Rhön-Klinikum
Since 2009 CFO of RHÖN-KLINIKUM AG
2006-2008 Head of RHÖN-KLINIKUM´s Management Controlling
2004-2005 CEO of Mannheim Nursing Home Group
2001-2005 Head of Corporate Development Mannheim University
Hospital
 2000-2001 Senior Consultant at Roland Berger’s Healthcare Practice




Stefan Höfer, Deutsche Börse AG
Professional Experience with Deutsche Börse AG
A Business Administration graduate, Stefan has over 20 years experience
with Deutsche Börse. Starting his career with the ‘Electronic Trading
System’ department he moved to the ‘New Market’ team in 1997. From
1999 he managed a number of projects developing exchanges in Central
and Eastern Europe. In 2001 Stefan was appointed Head of Marketing for
NEWEX Börse AG, the central and eastern European exchange. Since May
2002 he has been Key Account Manager for Life Science Issuers and
Listing Partners. Currently his role as Director and Expert includes
responsibilities for development and promotion of Deutsche Börse listing
activities in Russia & CIS.
12
Life Science Conference
Dr. iur. Dr. med. Adem Koyuncu, Mayer Brown LLP
Dr. Dr. Adem Koyuncu is double qualified as lawyer and medical doctor and
is one of the co-chairs of Mayer Brown’s global Life Sciences-practice. He
focuses his practice on advising and representing Life Sciences industry
clients. His clients include midsize and global and some of the leading
pharmaceutical, medical devices and nutrition companies. He also advises
investors in the Life Sciences-industry.
Prior to joining Mayer Brown, Adem worked for several years in the pharma
industry and practiced as medical doctor. He has an in-depth knowledge of the Life Sciences
industry. Adem assists clients in transactions and corporate matters. He also provides advice
on compliance, regulatory and liability matters. In 2008 and 2005, he received renowned
awards for his legal work.
He is named as "often recommended lawyer" for pharma and medical devices law by
Germany’s leading legal handbook. Adem is the author of numerous publications and a
frequent speaker on Life Sciences industry related topics. He is a lecturer at the Bucerius Law
School and the University of Düsseldorf. Adem is fluent in German, Turkish and English.
Stephan Leonhard, Asklepios Kliniken
 responsible for Accounting, Controlling, Tax, Risk-Management,
Corporate Finance, Internal Audit, Insurance, Legal and M&A
 with Asklepios since 2002
 previously CFO of various companies
 Dipl.-Kfm. (University of Mannheim)
 Tax Advisor (Ernst & Young)
Corporate Profile:
With a market share of over 20 percent, the Asklepios Group is one of the three largest
operators of private hospitals in Germany. The group’s strategy – which focuses on highquality, innovation and sustainable growth – has been rewarded with dynamic growth since its
formation 26 years ago. With its more than 44000 employees Asklepios runs more than 140
health facilities. At the end of 2011 about 1,7 billion of patients were medicated at facilities of
the Asklepios Group.
Asklepios has a strong growth record, is profitable and generates stable cash flows on the
basis of a long-term orientated business model. The group also has a sound financial structure
and a strong capital base. Asklepios is thus excellently positioned, both strategically and
commercially, to actively shape the structural transformation of the German healthcare
system.
13
Life Science Conference
Dr. Stephen Little, QIAGEN
Dr Stephen Little is a leading figure in the global personalized healthcare
and companion diagnostics industry. Co-founder and former CEO of DxS
Ltd, Dr Little led the company from its inception in 2001 to become the
market leader in the provision of molecular diagnostics for cancer. In
September 2009 DxS was acquired by QIAGEN, a global sample and assay
company, DxS is now QIAGEN Manchester Ltd, a global Center of
Excellence in Companion Diagnostics.
Dr Little has over 20 years experience in the pharmaceutical and
diagnostics sectors, and as VP of Personalized Healthcare at QIAGEN
continues to help shape the personalised medicine marketplace,
championing the cause for pharmaceutical partnering and companion
diagnostic provision in healthcare.
Manuela Mueller-Gerndt, Healthcare Leader, IBM
Manuela Mueller-Gerndt is a leading management executive in the
healthcare industry with a passion for technology and medicine and a
proven track record of business results in this market.
She started her career 15 years ago in the healthcare industry at one of
the Global Players for healthcare. In her current role with IBM, she is
focusing on generating proven healthcare outcomes by designing
innovative healthcare solutions for the entire healthcare industry in
Germany. Her clients include university hospitals, large private owned
hospital chains, public and private healthcare insurance organizations, medical technology
companies, pharma/life science organizations as well the Ministry of Health. Typical solutions
in the portfolio are healthcare analytics, healthcare transformation projects, health 2.0,
telemedicine, e-health and cross-solutions for care coordination, new go-to-market approaches
including shared research programs for prevention, chronic diseases, or personalized
medicine, genomics and translational medicine. Manuela has owns at IBM people and project
responsibility. Prior to her current role she led significant global healthcare projects for SME’s
in the medical-device sector i.e. innovative mobile imaging, 3D-visualization, and introduction
of flat panel technology in the mobile imaging market.
Manuela served for two years as Vice President for Ziehm Imaging GmbH, an innovative
medical imaging company where she led the turnaround team and was in charge for strategic
product innovations,marketing and education. She started her career at Siemens Medical
Solutions, first in charge of strategic healthcare projects, such as solution-driven technological
roll-out implementations and new business development for the healthcare industry, then
managing the entire global knowledge management and competitive intelligence initiative for
Siemens Medical Solutions both for employees and customers around the world. Manuela
holds a degree in business administration from the Universities in Munich and Rome. She
followed her executive and healthcare technology education at Duke University, M.I.T.,
Cambridge and Boston University (USA), published books and publications in German, English
and Chinese language and is invited speaker and significant influencer at several international
healthcare conferences.
Manuela is mother of eight year old twins and member of following organizations, where she
bridges the world of theory (ideas) and the practical reality for execution: M.I.T. Alumni,
Cambridge, U.S.A., Alumni of the Hanns Seidel Foundation Munich, Young Leaders Forum at
BMW Foundation Herbert Quandt, Coach for Entrepreneurship at the Chamber of Commerce
Munich, Lecturer for SME Leadership and Management at FOM Munich, Member of the
German Advisory Council for Global Change (Healthcare) etc.
14
Life Science Conference
Dr. Markus Manns, Union Investment Privatfonds GmbH
Markus Manns joined Union Investment in 2000 as Portfolio Manager Life
Sciences. He manages the award winning funds Unisector Biopharma and
Unisector Gentech and is also Co-chairman of the DVFA Commission Life
Science and member of the advisory board of Go-bio, a start-up program
from the Federal Ministry of Education and Research (BMBF).
Markus Manns graduated from Johannes Gutenberg University Medical
School Mainz in 1993 and received his doctorate degree in medicine the
same year. From 1993-1995 he worked as a Research Fellow at Thomas
Jefferson University in Philadelphia and published several scientific papers
in the area of acute renal failure and hemodialysis. He worked from 1996-1998 as Product
Manager Acute Therapies at Fresenius Medical Care in Bad Homburg and Milano and from
1999-2000 as Senior Consultant for Gemini Consulting in Bad Homburg.
Christian B. Teig, CompuGroup Medical AG
Mr. Christian B. Teig was born in Oslo, Norway, in 1965.
In October 2008, he was appointed Financial Director (CFO) of
CompuGroup Medical AG.
Prior to his appointment, Christian B. Teig held the position as CEO of
Profdoc ASA, a Norwegian listed e-Health company.
Before Christian B. Teig started to work for Profdoc in 2000, he worked in
the technology sector for Norsk Data and as a management consultant for
McKinsey & Company.
Christian B. Teig received his Bachelor of Science degree from the
University of California (Santa Barbara) in 1990 and his Master of
Business Administration degree from INSEAD (France) in 1995.
15
Life Science Conference
Prof. Dr. Jörg Vienken, Fresenius Medical Care Deutschland
Prof. Dr. Ing. Joerg Vienken has a degree in Chemical Engineering from the
Technical University of Darmstadt and a Doctoral Degree in Biophysics &
Engineering from the Technical University of Aachen (RWTH), both in
Germany.
After working as an Assistant Professor at the Institute for Biotechnology at
Würzburg University, he is active in the medical device industry since more
than 25 years. His focus is on medical device technology, biomaterials and
artificial organs.
Until moving to his recent position as Vice President "BioSciences" at
Fresenius Medical Care in Bad Homburg, he was Head of the Department of
Scientific Services at Akzo Nobel Membrana, Wuppertal, both in Germany.
Jörg Vienken has authored more than 300 publications & book chapters and 6 books with subject
to the Medical Device Industry, biological and artificial membranes, biomaterials, biocompatibility
and nephrology issues, as well as on Artificial Organs.
He is member of the Editorial Board of several scientific journals dedicated to Biomaterials,
Artificial Organs and Medical Device Technology.
JV currently served as President of the International Federation for Artificial Organs (IFAO) from
2009-2011, with IFAO being the umbrella society for the continental Artificial Organs Societies,
ASAIO (USA), JSAO (Japan) and ESAO (Europe). He is currently the Chairman of the Board of the
German Association of Biotech Companies (VBU).
Dr. Volker Wendel, AMEOS Group
AMEOS Group, founded 2002 in Zurich, is a leading provider of integrated
healthcare services throughout the German-speaking region. The company
operates an extensive network with more than 50 facilities encompassing
both acute general and psychiatric hospitals as well as long-term mental
and elderly care facilities.
Dr. Volker Wendel is Chief Financial Officer of AMEOS Group since 2007.
His areas of responsibility include financial reporting, controlling,
budgeting, strategic planning, financing and cash management. Prior to
AMEOS Dr. Wendel spent four years at the University Hospital of Essen
where he worked as Vice Administrative Director, Head of Corporate Planning and Managing
Director of West German Proton Therapy Center Essen (WPE) GmbH. In the latter function, he
was responsible for the so far biggest Public Private Partnership (PPP) project in the German
healthcare industry. Between 2001 and 2003, Dr. Wendel spent time as a consultant with
Roland Berger in their Public Services/Healthcare sector team, where he consulted particularly
healthcare service providers, public institutions and non-profit organizations.
Born in 1971, Dr. Wendel studied economics and business administration at the Universities
of Freiburg and Mannheim and earned his PhD in business administration from the University
of Mannheim. During his doctoral studies at the Chair of Public & Nonprofit Management, he
did some research projects in the United States, Canada and Australia.
16
Life Science Conference
Sponsors
DZ BANK GROUP
PARTNER IN THE VOLKSBANKEN RAIFFEISENBANKEN COOPERATIVE FINANCIAL NETWORK
The DZ BANK Group forms part of the German cooperative financial network, which comprises
more than 1,100 local cooperative banks and is one of Germany‘s largest private-sector
financial services organizations measured in terms of total assets. Within the cooperative
financial network, DZ BANK AG functions both as a central institution for over 900 cooperative
banks and their 12,000 branch offices and as a corporate bank.
The DZ BANK Group includes Bausparkasse Schwäbisch Hall, DG HYP, DZ PRIVATBANK Group,
R+V Versicherung, TeamBank, Union Investment Group, VR LEASING, and various other
specialized institutions. With their strong brands, the companies of the DZ BANK Group
constitute key pillars in the range of financial products and services offered by the cooperative
financial network. The DZ BANK Group sets out its strategy and range of services for the
cooperative banks and their customers through its four strategic business lines – retail
banking, corporate banking, capital markets, and transaction banking.
This combination of banking, insurance, home savings, and personal investment products and
services has a long and successful tradition in the cooperative financial network. The
specialized institutions in the DZ BANK Group provide top-class, highly competitive products at
reasonable prices within their specific areas of expertise. This ensures that the cooperative
banks in Germany are able to offer their clients a comprehensive range of outstanding
financial services.
PwC
PwC. 8,900 dedicated people at 28 locations. € 1.45 billion in turnover. The leading auditing
and consulting firm in Germany.
Our clients face diverse challenges, strive to put new ideas into practice and seek expert
advice. They turn to us for comprehensive support and practical solutions that deliver
maximum value. Whether for a global player, a family business or a public institution, we
leverage all of our assets: experience, industry knowledge, high standards of quality,
commitment to innovation and the resources of our expert network in over 158 countries.
Building a trusting and cooperative relationship with our clients is particularly important to us –
the better we know and understand our clients’ needs, the more effectively we can support
them.
17
Company Profile
As one of the world’s leading exchange organisations Deutsche Börse Group provides
investors, financial institutions and companies access to global capital markets. Our
business covers the entire process chain from securities and derivatives trading, clearing,
settlement and custody, through to market data and the development and operation of
electronic trading systems.
Our reliable systems and our integrity as a neutral provider form the basis of our business
philosophy. We operate to the most exacting standards to create products and services to
meet the needs of international financial markets. As a listed company we work to create
value for our customers and our shareholders.
The Deutsche Börse business model is based on liquidity of stock trading and by thus is
align with the interests of the listed company. Due to this Deutsche Börse is offering its
professional and efficient listing platform and services to facilitate the development of the
listed company entering the European market and to meet the need of investors.
18
Global Solutions.
Local Strength.
Mayer Brown is a leading global law firm with offices in major cities across the Americas, Asia
and Europe.
The unique opportunities and challenges of the life sciences industry require specific legal
know-how, technological expertise and international advice from an entrepreneurial perspective.
Our clients include life sciences companies as well as banks, funds, investment banks and other
investors in the life sciences sector. Our geographic reach and on-the-ground presence in most
of the world’s key business and finance centers allow us to assist our clients in structuring and
coordinating their transactions and legal matters.
Our in-depth experience in the life sciences sector, gained by working across business areas and
issues with life sciences companies and networking with leading industry organizations, provides
us with the necessary insights for handling the legal and regulatory challenges facing the global
pharmaceuticals, biotech and medical device industries.
For solutions with a future.
Your contact in Germany:
Dr. Dr. Adem Koyuncu
Partner – Lawyer and Physician
Co-Head Global Life Sciences Practice
T: +49 211 86224 283
[email protected]
Please visit our websites:
Life Sciences: www.mayerbrown.com/lifesciences
Capital Markets: www.mayerbrown.com/capitalmarkets
Mayer Brown llp
Bockenheimer Landstraße 98 -100
60323 Frankfurt am Main
Germany
Mayer Brown llp
Graf-Adolf-Platz 15
40213 Düsseldorf
Germany
Americas | Asia | Europe | www.mayerbrown.com
Mayer Brown LLP is a limited liability partnership established under the laws of the State of Illinois, U.S.A.
19
Life Science Conference
Organizational Details
Venue
Contact Details
Life Science Conference
DVFA Center
Mainzer Landstrasse 37-39
60329 Frankfurt am Main
It will be possible to reach you and the DVFA team during
the conference at the following number:
Phone: +49 / 69 / 24 24 94 08
Fax:
+49 / 69 / 24 24 94 09
DVFA Center
Mainzer Landstrasse 37-39
60329 Frankfurt am Main
Event Management
Heike Hambuch
eMail: [email protected]
Technical Support
Viktor Bart
eMail: [email protected]
Contact Details
DVFA GmbH
DVFA GmbH
Phone: +49 / 69 / 26 48 48 0
Fax:
+49 / 69 / 26 48 48 489
www.dvfa.de
Managing Director
Ralf Frank
eMail: [email protected], Phone: +49 / 69 / 26 48 48 0
Financial Communication
Karin Wenzel
eMail: [email protected], Phone: +49 / 69 / 26 48 48 101
20
Michael E. Porter, Harvard Business School, Institute for Strategy and
Competitiveness, Boston, MA, USA; Clemens Guth, Munich, Germany
Redefining German Health Care
Moving to a Value-Based System
The German health care system is on a collision course with budget realities. Costs are
high and rising, and quality problems are becoming ever more apparent. Decades of
reforms have produced little change to these troubling trends.
Why has Germany failed to solve these cost and quality problems? The reason is that
Germany has not set value for patients as the overarching goal, defined as the patient
health outcomes achieved per euro expended.
This book lays out an action agenda to move Germany to a high value system: care
must be reorganized around patients and their medical conditions, providers must
compete around the outcomes they achieve, health plans must take an active role in
improving subscriber health, and payment must shift to models that reward excellent
providers. Also, private insurance must be integrated in the risk-pooling system.
These steps are practical and achievable, as numerous examples in the book
demonstrate. Moving to a value-based health care system is the only way for Germany
to continue to ensure access to excellent health care for everyone.
2012 Approx. 330 p. Hard cover
► € 49.95 | £ 44.99 |
ISBN: 978-3-642-10825-9
forthcoming
Yes, please send me
____ copies Porter/Guth, Redefining German Health Care
ISBN: 978-3-642-10825-9 ► € 49.95 | £ 44.99
Testimonials
We must thank the authors of Redefining German Health Care for changing the language of the current health
care debate. Their book makes a passionate argument for moving the health care discussion beyond cost
control, health insurance premiums and risk pooling. It is health outcomes that matter to patients, not insurance
premiums per se.
Prof. Dr. Dr. Dr. Eckhard Nagel, Institute for Medical Management and Health Sciences University of Bayreuth
and Chief Medical Officer University Hospital Essen, Germany
The introduction of competition among health insurances in Germany was successful. However, it is long
overdue to instil value-adding competition to the provider side. This is convincingly demonstrated by Michael
Porter and Clemens Guth in their excellent adaption of the original Redefining Health Care book.
Prof. Dr. Norbert Klusen, Chief Executive Officer Techniker Krankenkasse, Hamburg, Germany
In the book Redefining German Health Care, Michael Porter and Clemens Guth establish clear, actionable
steps which providers and health plans should take to maximize patient value. They argue that every provider
should focus their service lines, measure outcomes and organise integrated care around medical conditions.
This book is inspiring and a must read for health care managers.
Prof. Dr. Karl Max Einhäupl, Chief Executive Officer Charité – Universitätsmedizin, Berlin, Germany
Physicians and provider organizations must make outcome measurement core to their activities. Outcome
measurement demonstrates that not the volume but the results of care matter. Superior providers will benefit
from transparency of results, either through pay-for-performance or simply through more patients. Redefining
German Health Care shows us convincingly how we can embark on this course.
Professor Dr. Dr. h.c. Peter C. Scriba, Chairman of the Research Board of the German Medical Association,
former Vice-President of Health Care Advisory Council and Chief Medical Officer of Ludwig-MaximiliansUniversity Hospital, Munich, Germany
The book “Redefining German Health Care” by Michael Porter and Clemens Guth provides a fact-based
analysis of the development of the German health care system. On the one hand, the analysis and assessment
demonstrates the system’s substantial achievements (also with respect to other countries), while, on the other
hand, it speaks clearly about the system’s shortcomings, which are highlighted by concrete examples. The
reader is presented with logical arguments for structurally changing the health care system, building on the
already achieved benefits. Both authors rightly assume that better quality in conjunction with appropriate
financing and incentive schemes will lead to higher cost efficiency, as shown in other industries. The system
will not improve without an honest debate over the current system’s challenges. This book makes a significant
contribution to that process.
Prof. Dr. Jürgen Wettke, Director Healthcare Practice McKinsey & Company, Duesseldorf, Germany
Venue
DVFA Center
Mainzer Landstrasse 37-39
D-60329 Frankfurt am Main
Tel.: +49 (0) 69 24 24 94 08
DVFA GmbH
Karin Wenzel
Financial Communication
Tel.: +49 (0) 69 26 48 48 101
Fax: +49 (0) 69 26 48 48 489
Mail: [email protected]
Web: www.dvfa.de
DVFA – Society of Investment Professionals in Germany
DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently,
DVFA has approx. 1,600 individual members representing over 400 investment firms,
banks, asset managers, consultants and counselling businesses. DVFA assures the
credibility of the professionals and the integrity of the market by offering internationally
recognised qualification programmes, by providing platforms for professional financial
communication, and by effective self-regulation.
Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access
to a pan-European network with more than 17,000 investment professionals in 26 nations. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is
part of a worldwide network of more than 60,000 investment professionals.
Content: DVFA GmbH
Design: ReichDesign, Frankfurt
Picture: www.shutterstock.com
Subject to modifications. Copyright 2012 DVFA GmbH.